|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 14/575 | (2006.01) |
| C07K 14/605 | (2006.01) | ||
| A61K 38/26 | (2006.01) |
| (11) | Number of the document | 3242887 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16703620.1 |
| Date of filing the European patent application | 2016-01-05 | |
| (97) | Date of publication of the European application | 2017-11-15 |
| (45) | Date of publication and mention of the grant of the patent | 2019-08-14 |
| (46) | Date of publication of the claims translation | 2019-11-11 |
| (86) | Number | PCT/US2016/012124 |
| Date | 2016-01-05 |
| (87) | Number | WO 2016/111971 |
| Date | 2016-07-14 |
| (30) | Number | Date | Country code |
| 201562101488 P | 2015-01-09 | US |
| (72) |
ALSINA-FERNANDEZ, Jorge, US
BOKVIST, Bengt Krister, US
COSKUN, Tamer, US
CUMMINS, Robert Chadwick, US
|
| (73) |
Eli Lilly and Company,
Lilly Corporate Center, Indianapolis, IN 46285,
US
|
| (74) |
Liudmila GERASIMOVIČ,
IĮ "Liudmila Gerasimovič, Patentinis patikėtinis", Vingrių g. 13-42, LT-01141 Vilnius,
LT
|
| (54) | Junginiai koagonistai GIP ir GLP-1 |
| GIP AND GLP-1 CO-AGONIST COMPOUNDS |
| Payment date | Validity (years) | Amount | |
| 2025-12-17 | 11 | 289.00 EUR |
| 2027-01-05 |